ABOUT THE COMPANIES
Atlantic Avenue, Suite 102
Inc., a California corporation, is a clinical-stage biotechnology company targeting degenerative diseases. BioTime’s programs
are based on two core proprietary technology platforms: cell replacement and cell/drug delivery. With BioTime’s cell replacement
platform, BioTime is creating new cells and tissues with BioTime’s pluripotent and progenitor cell technologies. These cells
and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases. BioTime’s
cell/drug delivery programs are based upon BioTime’s proprietary HyStem® cell and drug delivery matrix
technology. HyStem® was designed to provide for the transfer, retention, engraftment and metabolic support
of cellular replacement therapy.
common shares are listed on NYSE American under the symbol “BTX.”
information about BioTime and its subsidiaries is included in the documents incorporated by reference in this joint proxy statement/prospectus.
See the section entitled “Where You Can Find More Information.”
is a clinical-stage biotechnology company dedicated to developing pluripotent stem cell-derived therapies to treat neurological
conditions associated with demyelination and cellular immunotherapies to treat cancer. Asterias has industry-leading technology
in two cell types, each with broad potential applicability: (1) oligodendrocyte progenitor cells, which become oligodendrocytes
that have the potential to remyelinate axons within the central nervous system and perform other restorative functions, and (2)
antigen-presenting dendritic cells, which train T-cells in the immune system to attack and destroy solid or liquid tumor cells
across multiple types of cancer. Asterias currently has three clinical-stage therapeutic programs, focusing on spinal cord injury,
non-small cell lung cancer and acute myeloid leukemia.
Common Stock is listed on the NYSE American under the symbol “AST.”
information about Asterias is included in documents incorporated by reference in this joint proxy statement/prospectus. See the
section entitled “Where You Can Find More Information.”
Merger Sub, Inc.
Atlantic Avenue, Suite 102
Merger Sub, Inc., a wholly owned subsidiary of BioTime, is a Delaware corporation that was formed on November 5, 2018 for the
purpose of effecting the Merger. Upon completion of the Merger, Merger Sub will be merged with and into Asterias, with Asterias
surviving as a wholly owned subsidiary of BioTime. Merger Sub has not conducted any activities other than those incidental to
its formation and the matters contemplated by the Merger Agreement in connection with the Merger.